Nanocarrier Breakthroughs: Revolutionizing Cancer Treatment with Nanotechnology

Cancer remains a complex and multifactorial disease characterized by genetic mutations, epigenetic changes, and alterations in cellular signaling pathways. While traditional treatments such as surgery, chemotherapy, and radiation have been the backbone of cancer therapy, their limitations, including drug resistance, recurrence, and significant side effects, have driven the search for more targeted and personalized treatment approaches. This review provides an in-depth exploration of recent advances in cancer research and therapy, focusing on molecular mechanisms, genetic alterations, and the tumor microenvironment, all of which play pivotal roles in tumor initiation and progression. Key discoveries in oncogenes, tumor suppressor genes, and immune evasion strategies have led to the development of targeted therapies and immunotherapies. These advancements have revolutionized the treatment landscape, with therapies like immune checkpoint inhibitors, CAR T-cell therapy, and personalized medicine offering improved patient outcomes. However, challenges such as tumor heterogeneity, acquired drug resistance, therapy-related toxicities, and the high costs of these novel treatments continue to limit their effectiveness and accessibility. The review also delves into emerging therapeutic strategies, including next-generation immunotherapies, precision oncology enhanced by artificial intelligence, tumor vaccines, microbiome-based therapies, and the application of nanotechnology for drug delivery. As cancer therapies evolve, addressing these challenges is crucial for future breakthroughs. The review emphasizes the need for continued research into overcoming resistance mechanisms, reducing treatment-related side effects, and enhancing global access to cutting-edge treatments. Looking ahead, the integration of new technologies and the development of more equitable healthcare strategies will be essential to ensuring that advances in cancer therapy translate into improved survival and quality of life for patients worldwide. In conclusion, while remarkable progress has been made in cancer treatment, a multifaceted approach that blends scientific innovation, precision medicine, and healthcare accessibility will be key to overcoming the ongoing challenges in the fight against cancer. Keywords: Cancer Mechanism, Therapy, Advances, Challenges, Future Directions

This paper describes a novel serendipitous discovery to successfully treat cancer with improved efficiency emerged while using Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy (originally discovered to prevent or treat nosocomial infections) as an adjuvant therapy along with the immune checkpoint therapy and other conventional cancer therapies. This new discovery is named as “Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Adjuvant Cancer Therapy”. Cancer is rising as a global epidemic, currently killing over 9 million people every year. This figure is supposed to get up to 13 million by the year 2030. The cancer epidemic is more prevalent in the Western countries than Eastern countries. The cost of treating cancer was $290 billion in the year 2010 and it is supposed to get up to $458 billion/year by the year 2030. Recently checkpoint immune therapy is showing great promise as a treatment tool. Yet the global success in treating the cancer is only 20% or slightly higher, with all the advancements and discoveries. A new paradigm shift in cancer treatment has been discovered as serendipitous discovery to enhance the efficiency of the existing cancer therapies significantly. This serendipitous discovery came as a surprise while running community based clinical trials using the novel discovery of Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy to prevent or cure the hospital acquired or nosocomial infections, which are affecting over six million people with severe mortality. Several physicians have observed that Dr. Reddy’s Probiotic therapy given for prevention or control of nosocomial infections significantly helped the recovery of cancer patients who were also receiving standard cancer therapies. This article outlines the mechanism by which Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy assist to cure cancer at a much faster pace, with the least side effects, when used as adjuvant therapy along with the immune checkpoint therapy, and other standard cancer therapies. Details are presented how the PD-1 and CTLA-4 blockade therapy works to reduce cancer and also the possible scientific explanations why such an immune checkpoint therapy only works on limited cancer cases. The effect of Multiple Mixed Strain Probiotics on establishing the immune tolerance through reduction of local or systemic inflammation is also outlined. The possible biological and immunological mechanisms of how Multiple Mixed Strain Probiotic Therapy significantly enhances the immune checkpoint therapy (PD-1 and CTLA-4 blockade) has been presented with explicit details. The details are also presented showing how Multiple Mixed Strain Adjuvant Therapy can minimize or significantly reduce the unpleasant side effects of the current conventional and immune checkpoint cancer therapies. Practical clinical and experimental data presented to show the significance of Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic Therapy, as an adjuvant therapy, along with the standard cancer therapies to improve the cancer treatment efficiencies by up to 60%. Evidence is presented to illustrate and point out that the current FDA regulations will allow the use of Dr. M.S. Reddy’s Multiple Mixed Strain Probiotic (Therapy) as nutritional supplement, since the probiotic strains used are categorized as food grade and GRAS (Generally Regarded as Safe), as per the 21 Code of Federal Regulations of the Food and Drug Administration. Details are presented with genus and species identification of individual probiotic strains used in the Multiple Mixed Strain Probiotic Therapy. Thus special and formal FDA approval is not required to use them as adjuvants to improve the efficiency of traditional cancer therapies. Finally the scientific reasoning is presented with evidence to illustrate the utmost urgency and necessity of using Dr. M.S. Reddy’s “Multiple Mixed Strain Probiotic Therapy” along with the immune checkpoint therapy and other traditional cancer therapies to protect the lives of millions of people dying with cancer annually.

Recent advances in cancer therapy have resulted in significant improvements in long-term survival of patients. However, a considerable price has been paid in terms of side effects associated with treatment. The most clinically impacting complication, feared both by oncologists and cardiologists, is the development of asymptomatic or symptomatic left ventricular dysfunction, possibly leading to heart failure, induced not only by conventional cancer therapy, but also by novel, targeted agents. At present, left ventricular ejection fraction assessment represents the standard for cardiac monitoring during and after cancer therapy. More recently, a newer approach based on the measurement of cardiospecific biomarkers has been proposed. However, an evidence-based approach to recognize, care and prevent anticancer related heart failure is still lacking. In this chapter, we reviewed possible pathophysiologic mechanisms and risk factors, and we discussed the currently available approaches of monitoring, prevention and treatment of anticancer drug-induced cardiotoxicity.

Glioblastoma is the most common and aggressive malignant primary brain tumour. Patients with glioblastoma have a median survival of only around 14.6 months after diagnosis, despite the availability of various conventional multimodal treatments including chemotherapy, radiation therapy, and surgery. Therefore, photodynamic therapy (PDT) has emerged as an advanced, selective and more controlled therapeutic approach, which has minimal systemic toxicity and fewer side effects. PDT is a less invasive therapy that targets all cells or tissues that possess the photosensitizer (PS) itself, without affecting the surrounding healthy tissues. Polymeric NPs (PNPs) as carriers can improve the targeting ability and stability of PSs and co-deliver various anticancer agents to achieve combined cancer therapy. Because of their versatile tuneable features, these PNPs have the capacity to open tight junctions of the blood–brain barrier (BBB), easily transport drugs across the BBB, protect against enzymatic degradation, prolong the systemic circulation, and sustainably release the drug. Conjugated polymer NPs, poly(lactic-co-glycolic acid)-based NPs, lipid–polymer hybrid NPs, and polyethylene-glycolated PNPs have demonstrated great potential in PDT owing to their unique biocompatibility and optical properties. Although the combination of PDT and PNPs has great potential and can provide several benefits over conventional cancer therapies, there are several limitations that are hindering its translation into clinical use. This review aims to summarize the recent advances in the combined use of PNPs and PDT in the case of glioblastoma treatment. By evaluating various types of PDT and PNPs, this review emphasizes how these innovative approaches can play an important role in overcoming glioblastoma-associated critical challenges, including BBB and tumour heterogeneity. Furthermore, this review also discusses the challenges and future directions for PNPs and PDT, which provides insight into the potential solutions to various problems that are hindering their clinical translation in glioblastoma treatment.

The unchecked growth and spread of aberrant cells describe a widely diverse collection of disorders that collectively constitute cancer. Conventional therapies for cancer, including radiation therapy, chemotherapy, and surgery, have increased the chances of survival significantly in most patients. These traditional methods usually result in low tumor or tumor cell specificity, significant systemic toxicity, and the development of drug resistance. This review summarizes updates in cancer therapy, some of which include cutting-edge therapies represented by CAR-T therapy, targeted therapies, gene therapy, arginine-depriving therapy, mitochondria-targeted therapies, neutrophil-targeted therapies, and the latest PROTAC technology for proteolysis-targeting chimera. It has emphasized mechanisms underlying these new therapeutic strategies and their translational potential for treating human cancers. We further discuss, for each approach, the challenges, limitations, side effects, and delivery systems. The review proceeds with a dynamic change in the landscape of cancer research in biology, where machine learning and artificial intelligence are increasingly important to improve our understanding of the mechanisms of cancer and treatment responses. We also describe the potential of stem cell therapy, metabolomics, and novel drug delivery systems toward better patient outcomes. The paper pulls together some of the current research findings and results of clinical trials in new therapeutic developments and emerging areas of research that hold out exciting promises for the future progress of cancer treatment.

Immune-Related Adverse Events and Outcomes in Patients with Advanced Non–Small Cell Lung Cancer: A Predictive Marker of Efficacy?

Background: Cancers of the gastrointestinal (GI) tract are the common leading cause of cancer-related death in the world. Recent advances in cancer therapies such as intensive multidrug chemotherapy and molecular targeted treatment have improved therapeutic efficacy; however, the outcomes are not satisfied. Moreover, these therapies also cause severe side effects. New type of cancer therapies is urgently needed to improve the outcomes and to reduce side effects of GI tract cancers. Summary: This account is a comprehensive review article on the newly developed, photochemistry-based cancer therapy named as near-infrared photoimmunotherapy (NIR-PIT). NIR-PIT is a highly selective tumor treatment that employs an antibody-photoabsorber conjugate, which is activated by near-infrared light. A world-wide phase 3 clinical trial of NIR-PIT against recurrent head and neck cancer patients is currently underway. NIR-PIT differs from conventional cancer therapies such as surgery, chemotherapy, and radiation in its selectivity for killing cancer cells and cells treated with NIR-PIT leading to immunogenic cell death. Preclinical research in animals with combining cancer-targeting NIR-PIT and other cancer immunotherapies could lead to responses not only in local tumor but also in distant metastases. NIR-PIT also leads to an immediate and dramatic increase in vascular permeability after therapy. From these aspects, NIR-PIT appears to be a promising new form of cancer therapy. NIR-PIT could be readily translated into clinical use for virtually any cancers in the near future provided suitable humanized antibodies are available. Here, we describe the specific advantages and applications of NIR-PIT in the GI tract. Key Messages: We believe that NIR-PIT with NIR excitation light, which can be delivered via a fiber optic diffuser through endoscopes, is a promising method for a new treatment of GI cancers.

Polymeric nanoparticles are a promising novel drug delivery system and have advantages in cancer therapy. Etoposide is an anticancer agent that is used in the treatment of a variety of malignancies. The aim of the present study was to prepare and evaluate novel polymeric nanoparticles containing etoposide. A 32 full factorial design was used to study the effect of Eudragit EPO and Pluronic F-68 on the characterization of nanoparticle suspensions. The polymeric nanoparticles were prepared by nanoprecipitation technique. The prepared nanoparticles was evaluated by percentage yield, drug polymer compatibility using fourier transform infrared (FTIR) spectroscopy and differential scanning calorimetric (DSC) analysis, drug content, entrapment efficiency, zeta potential, particle size, scanning electron microscopy, X-ray diffraction, in vitro drug release studies, kinetic modeling, stability studies, and in vivo animal studies. Response surface plots were studied, which were generated using PCP dissolution software. Scanning electron microscopic studies confirmed their porous structure with a number of nanochannels. The FTIR spectra showed the stable character of etoposide in a mixture of polymers and revealed the absence of drug-polymer interactions. The DSC study revealed that the drug was involved in complexation with nanoparticles. The average particle size of etoposide nanoparticles was in the range of 114.4 nm to 136.7 nm. The zeta potential values were attained to ensure good stability of nanosuspensions. In vitro release of the drug from nanoparticles follows the Peppas model and showed controlled release behavior for a period of 24 h. The optimized nanoparticles were subjected to stability studies at 4°C in a refrigerator and the most suitable temperature for storage of etoposide nanoparticles found. The average targeting efficiency of drug-loaded nanoparticles was 41.88±0.030% of the injected dose in the liver, 25.66±0.320% in the spleen 13.82±0.090% in the lungs, 4.52±0.300% in the kidney, and 4.18±0.490% in the brain. Etoposide loaded nanoparticles was found to be effective in sustained release.

8 - Nanomedicine advances in cancer therapy

Nanocarriers can penetrate the tumour vasculature through its leaky endothelium and, in this way, accumulate in several solid tumours. This is called the enhanced permeation and retention (EPR) effect. Together with nanocarriers whose surface is tailored for prolonged blood circulation times, the concept is referred to as passive targeting. Targeting ligands, which bind to specific receptors on the tumour cells and endothelium, can be attached on the nanocarrier surface. This active targeting increases the selectivity of the delivery of drugs. Passive and active drug targeting with nanocarriers to tumours reduce toxic side-effects, increase efficacy, and enhance delivery of poorly soluble or sensitive therapeutic molecules. In this review, currently studied and used passive and active targeting strategies in cancer therapy are presented.

Nano-delivery of STING agonists: Unraveling the potential of immunotherapy.

Objective To explore the advancements and therapeutic potential of nanocarrier-based drug delivery systems in improving drug administration, targeting efficiency, and patient outcomes, particularly in complex disease management. Significance Traditional drug delivery methods often suffer from limited targeting ability, poor bioavailability, and increased side effects. Nanocarriers, such as liposomes, dendrimers, polymeric nanoparticles, and solid lipid nanoparticles, offer innovative solutions by enabling site-specific delivery, controlled release, and enhanced therapeutic indices, thereby transforming pharmaceutical care. Methods This review examines the current literature and recent innovations in nanocarrier design and application. It highlights stimulus-responsive systems (e.g. pH- or temperature-sensitive nanocarriers) and assesses their roles in treating conditions such as cancer, rheumatoid arthritis, and neurological disorders. This study also analyzes technological trends and translational challenges in clinical applications, including regulatory and safety concerns. Results Recent developments in nanotechnology have enabled the creation of multifunctional, targeted, and stimuli-responsive nanocarriers capable of delivering therapeutic agents with improved precision and efficacy. These systems significantly enhance drug absorption and retention at the target site, provide sustained release, and minimize systemic side effects of the drug. Preclinical and early clinical data support their effectiveness in overcoming the limitations of conventional therapies. Conclusions Nanocarrier-based drug delivery systems represent a paradigm shift in therapeutic strategies, offering precision-targeted treatment with improved efficacy and safety. Despite regulatory and translational challenges, continued research and innovation are accelerating their path to clinical adoption, establishing nanocarriers as the cornerstone of personalized medicine in cancer therapy.

Photodynamic Therapy: Standard of Care for Palliation of Cholangiocarcinoma?

Comment on “Anastrozole (Arimidex ™) versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: survival analysis and updated safety results” by J.-M. Nabholtz et al.

Cancer causes millions of deaths. Cancer occurs in almost any body organ when abnormal cells grow rapidly and spread to other tissues and organs. Cancer development is induced by genetic and cellular level abnormalities that facilitate tumour proliferation. Chemotherapy is a common curative method for cancer treatment. Conventional chemotherapeutic drugs are non-selective, have a short circulation half-life, and cause side effects. These shortcomings can be solved by using polymeric nanoparticles, which are effective as drug delivery agents with unique physicochemical properties that allow them to carry drugs with high efficacy, proper penetration and efficient targeting. Polymeric nanoparticles have unique sizes that help to target different types of cancer, and to release the drug into the cancerous cells. Polymeric nanoparticles have been recently used to entrap drug combinations that are more efficient than single drug nanosystems. This chapter reviews combinational therapy, polymer-based nanoparticles with entrapped combination of drugs, and the mechanism of the drug delivery towards solid tumours by active and passive targeting. Recent innovations, applications and future progress in cancer therapy using multiple drug regimens are also discussed.KeywordsPolymeric nanoparticleCombination of drug therapySolid tumorsActive and passive targeting